

Valsartan Prevented Neointimal Hyperplasia and Inhibited SRSF1 Expression and the TLR4–iNOS–ERK–AT1 Receptor Pathway in the Balloon-injured Rat Aorta

Yonghong LI^{1*}, Junjie GUO^{1*}, Haichu YU¹, Xin LIU¹, Jingwei ZHOU², Xianming CHU¹, Qingke XU¹, Tingru SUN³, Liang PENG¹, Xi YANG¹, Xilong TANG¹

**These authors contributed equally to this work*

¹Department of Cardiology, Affiliated Hospital of Qingdao University, Qingdao, China,

²Department of Emergency, Affiliated Hospital of Qingdao University, Qingdao, China,

³Department of Cardiology, Zibo First Hospital, Zibo, China

Received September 24, 2020

Accepted April 22, 2021

Epub Ahead of Print June 2, 2021

Summary

Valsartan has the potential to attenuate neointimal hyperplasia and to suppress the inflammatory response. This study aimed to evaluate the role of valsartan in neointimal hyperplasia and the toll-like receptor 4 (TLR4)-nitric oxide synthase (NOS) pathway in the balloon-injured rat aorta. Forty-eight Wistar rats were randomly allocated to three groups: sham control (control), balloon-injured group (surgery), and balloon-injured+valsartan-treated group (valsartan). Rats were killed at 14 and 28 days after balloon-injury, and then the aortic tissues were collected for morphometric analysis as well as for measurements of the mRNA or protein expression of angiotensin II, angiotensin II type 1 (AT1) receptor, angiotensin II type 2 (AT2) receptor, TLR4, endothelial nitric oxide synthase (eNOS), inducible NOS (iNOS), serine/arginine-rich splicing factor 1(SRSF1) and extracellular signal regulated kinase (ERK). Valsartan at a dose of 20 mg/kg/day markedly decreased neointimal hyperplasia in the aorta of balloon-injured rats, and significantly reduced the mRNA or protein expression of TLR4, AT1 receptor, SRSF1 and phosphorylated-ERK (p-ERK) as well as the aortic levels of iNOS (all $p<0.05$). Moreover, valsartan increased the eNOS level and AT2 receptor mRNA and protein expression levels (all $p<0.05$). Valsartan prevented neointimal hyperplasia and inhibited SRSF1 expression and the TLR4-iNOS-ERK-AT1 receptor pathway in the balloon-injured rat aorta.

Key words

Valsartan • Aorta • Neointimal hyperplasia • Balloon injury • Toll-like receptor 4 • Nitric oxide synthase

Corresponding author

Yonghong Li. Department of Cardiology, Affiliated Hospital of Qingdao University, No. 59 Haier Road, Qingdao 266003, China. E-mail: liyonghong662020@126.com

Introduction

Percutaneous coronary intervention (PCI) is a generally accepted therapy for treating coronary heart disease. Restenosis remains an important complication with the use of angioplasty and stents. Within 6 months, restenosis occurs in 32-55 % of all angioplasties, dropping to 17-41 % in the bare metal stent area (Buccheri *et al.* 2016). However, a new complication in-stent restenosis (ISR) arises from neointimal hyperplasia. Although the use of drug-eluting stents reduce the incidence of ISR to 5 %-10 % (Paramasivam *et al.* 2020), ISR remains a serious concern as late stent complications and drug eluting stent (DES) and ISR treatment continue to be challenging complications for interventional cardiologists (Alraies *et al.* 2017).

Neointimal formation after vascular injury is the critical pathological process of ISR. Activated vascular smooth muscle cells (VSMCs) respond to local stimulation and migrate from the media into the lumen of the vessel, participating in the process of restenosis. Serine/arginine-rich splicing factor 1 (SRSF1),

an essential splicing factor, promotes VSMC proliferation and injury-induced neointima formation. Vascular injury *in vivo* and proliferative stimuli *in vitro* were indicated to stimulate SRSF1 expression (Xie *et al.* 2017). Moreover, local inflammation after vascular injury also contributes to the development of restenosis (Araújo *et al.* 2015, Joviliano *et al.* 2011, Yoneda *et al.* 2013). Toll-like receptor 4 (TLR4), a member of the pattern recognition receptor family, participates in the inflammatory response after vascular injury (Den Dekker *et al.* 2010, Zou *et al.* 2019), and has been implicated as a potential clinical biomarker in patients who develop in-stent restenosis (Liang *et al.* 2016). Decreased nitric oxide (NO) production due to endothelial denudation leads to VSMC proliferation and migration. Endogenous NO is usually generated by endothelial nitric oxide synthase (eNOS), inducible NOS (iNOS), and neuronal NOS (nNOS) (Forstermann and Sessa 2012). Induction of iNOS production subsequently promotes the inflammatory response and accelerates restenosis (Chyu *et al.* 1999). In contrast, activation of eNOS can decrease neointimal formation after arterial injury (Janssens *et al.* 1998). Therefore, the TLR4-iNOS pathway can provide an emerging target for the prevention of restenosis.

Angiotensin II, a major mediator of the rennin-angiotensin system, acts through angiotensin II type 1 (AT1) and angiotensin II type 2 (AT2) receptors. Valsartan is regarded as a widely used AT1 receptor blocker (Huang *et al.* 2014). Our previous studies have shown that valsartan can reduce neointimal hyperplasia of the rat aorta via activating the angiotensin-converting enzyme 2 (ACE2)-angiotensin-(1-7)-Mas axis, inhibiting the AT1 receptor, and upregulating heme oxygenase-1 (Li *et al.* 2012, Li *et al.* 2014, 2016). Valsartan was proved to exert anti-inflammatory effects in clinical (Kintscher *et al.* 2010) and experimental (Iwashita *et al.* 2012, Hadi *et al.* 2015) studies. Previous study suggested that valsartan-eluting stents can inhibit neointimal hyperplasia post-stent implantation by reducing VSMC proliferation and collagen deposition (Guihua *et al.* 2010). Clinically, valsartan has yielded a beneficial effect by preventing in-stent restenosis after stenting (Peters 2008). However, the effects of valsartan on neointimal hyperplasia, the upstream signaling pathways of TLR4 and other proinflammatory cytokines in the balloon-injured rat aorta need to be further explored. Therefore, this study sought to evaluate the role of valsartan in neointimal hyperplasia, the TLR4-NOS pathway and SRSF1 expression in the balloon-injured rat aorta.

Materials and Methods

Drug and reagents

Valsartan was provided by Novartis Pharma Ltd. (Beijing, China). The angiotensin II radioimmunoassay kit was obtained from the Institute of Radioimmunoassay of the People's Liberation Army General Hospital, China. The NOS reagent kit was obtained from the Nanjing Jiancheng Institute of Biological Engineering, China. Polyclonal anti-TLR4, anti- β -actin, anti-AT1, anti-AT2, and antiphospho-ERK were provided by Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA. Polyclonal anti-SRSF1 was provided by Thermo Fisher Inc., Waltham, MA, USA.

Animals and experimental protocol

All the experimental protocols were performed in accordance with the Guidelines for the Care and Use of Laboratory Animals of Qingdao University (Number of Ethic Committee: QYFY WILL 25705). A total of 48 adult male Wistar rats weighing 300-350 g were provided by the Qingdao Animal Center, and housed at a temperature at 22 °C and 35 \pm 5 % humidity under a 12-h dark-light cycle. All rats were fed on a laboratory diet of rat chow and freely accessed to water. These rats were randomly allocated to three groups: sham control group (control group), balloon-injured group (surgery group), and balloon-injured+valsartan-treated group (valsartan group) (n=16 in each group). Neointimal hyperplasia of aortas was established using endothelial denudation with a 2F balloon dilation catheter. Briefly, rats were anesthetized by 0.6 % sodium pentobarbital (5ml/kg) intraperitoneally. The balloon catheter entered the thoracic aorta and abdominal aorta through the left common carotid artery. The balloon was inflated and passed with rotation three times in different directions. The success of aortic denudation was determined by injection of 2 ml/kg 0.5 % Evan's blue at 60 min after surgery (Li *et al.* 2008). The sham control rats underwent the same surgery except for balloon injury. The valsartan-treated rats received 20 mg/kg/day valsartan (dissolved in normal saline) via gastric gavage. Treatments started 24 h before balloon injury and continued until day 14 or day 28 post-surgery. The same volumes of 0.9 % saline solution were administered to the sham control and surgery rats.

Histological analysis

Rats were anesthetized by 0.6 % sodium

pentobarbital and sacrificed by cervical dislocation at 14 days and 28 days post-surgery, respectively. Thoracic aortic tissues in length of 4-5 cm were collected immediately. Other harvested aortic tissues were then immediately frozen in liquid nitrogen until a further analysis. Collected aortic tissues were cut into 5- μ m sections for hematoxylin-eosin (HE) staining and immunofluorescence. Images of neointimal hyperplasia were visualized under a light microscope at 200 \times magnification. Morphometric determinations of the intimal and medial thicknesses were quantified using an image analyzer (JEDA801 series, Science-Technology Development Co., China). The expression of SRSF1 protein was detected in immunofluorescence under a fluorescence microscope (DS-Ri2, Nikon Co., Japan) according to the previous report (Zaqout *et al.* 2020).

Measurement of angiotensin II and NOS in aortic tissues

Collected thoracic aortic tissues (35 mg in each group) were homogenized and centrifuged at 3000 rpm for 20 min, and then the supernatant was collected. The aortic angiotensin II levels were determined by a radioimmunoassay kit, according to the manufacturer's protocol. The iNOS and eNOS levels in aortic tissues were detected using chemical methods in accordance with the manufacturer's instructions.

Reverse transcription polymerase chain reaction

(RT-PCR)TLR4, AT1 receptor, and AT2 receptor mRNA expression levels were detected by the reverse transcription polymerase chain reaction (RT-PCR). Trizol reagent (Invitrogen, Carlsbad, CA, USA) was used to extract total RNA from the frozen aortic samples, according to the manufacturer's protocol. The integrity of extracted RNA was confirmed spectrophotometrically at 260 nm and 280 nm wavelengths. GAPDH was chosen as an internal control. The primer sequences were as follows: TLR4 (304 bp), 5'-TGGCATCATCTTCATTGTCC-3' (Forward) and 5'-GTCCACAGCAGAAACCCAGA-3' (Reverse), AT1 receptor (444 bp), 5'-CACCTATGTAAGATCGCTTC-3' (Forward) and 5'-GCACAATCGCCATAATTATCC-3' (Reverse), AT2 receptor (536 bp), 5'-TGAGTCCGCATTTAACTGC-3' (Forward) and 5'-ACCACTGAGCATATTTCTCGGG-3' (Reverse), GAPDH (161 bp), 5'-AGATGGTGAAGTCCGGTGTG-3' (Forward) and 5'-CTTGCCGTGGGTAGAGTCAT-3' (Reverse). The reaction was conducted on an ABI PRISM 7000 Sequence System (Applied Biosystems, Foster City,

CA, USA) under the following conditions: 95 °C for 3 min, 98 °C for 10 s, 57 °C for 10 s, and 72 °C for 30 s (total of 40 cycles), then a final extension for 10 min. The amplified PCR product was checked and analyzed by a gel imaging analyzer. Target mRNA expression was normalized to GAPDH mRNA expression for quantification.

Western blot analysis

Aortic TLR4, AT1 receptor, AT2 receptor, and p-ERK protein expression levels were detected by Western blot analysis. Briefly, 20 μ g of protein was resolved by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PGE), and transferred to a polyvinylidene fluoride membrane. The membranes were blocked with nonfat milk, and then incubated with anti-TLR4 (1:100 dilution), anti-AT1 (1:50 dilution), anti-AT2 (1:50 dilution), anti-phospho-ERK (1:100 dilution), or anti- β -actin (1:500 dilution), and subsequently incubated with the secondary antibody at 1:1250 dilution. Protein bands were visualized with an enhanced luminescence reagent and visualized using a Flurochem 9900-50 digital gel imaging system (Alpha Innotech Co., San Leandro, CA, USA). The optical density of each band was normalized to that of β -actin from the same sample.

Statistical analysis

Statistical analysis was performed using Statistical Product and Service Solutions (SPSS) version 16.0 (SPSS, Inc., Chicago, IL, USA). Values were expressed as the mean \pm standard deviation (SD). For the values of repeated measurements, two-way analysis of variance was performed. A statistical significance was set as $p < 0.05$.

Results

Effects of valsartan on neointimal hyperplasia in the balloon-injured rat aorta

On 14th day post-surgery, compared to the control (Fig. 1A), HE staining showed that most injured surfaces were covered by endothelial cells, and there was a large amount of VSMC proliferation. In addition, the intima was apparently tortuous, and neointimal hyperplasia was predominant (Fig. 1B). On 28th day post-surgery, compared to the control (Fig. 1D), endothelial cells almost covered all injured surfaces, and there was obvious VSMC proliferation as well as




Fig. 1. Representative hematoxylin-eosin staining images of neointimal hyperplasia in different groups (magnification, $\times 200$). The sham control rats exhibited a normal intima and media of the aorta at 14 (A) and 28 (D) days after surgery, the balloon-injured rats showed hyperplastic intima with endothelial cells and proliferative VSMCs (B and E), the valsartan-treated rats showed less intimal and medial hyperplasia (C and F). Image analysis of the intimal (G) and medial (H) thicknesses. Data are shown as the mean \pm SD ($n = 6$). * $p < 0.05$, ** $p < 0.01$ vs the control group, and $\Delta p < 0.05$ vs the surgery group. The solid line with double arrow represented media and the empty line with double arrow represented intima. The solid triangle represented proliferative VSMCs and empty triangle represented endothelial cells.





Fig. 2. Effects of valsartan on aortic angiotensin II (A), eNOS (B), and iNOS (C) levels. Data are shown as the mean \pm SD ($n = 6$). * $p < 0.05$, ** $p < 0.01$ vs the control group, and $\Delta p < 0.05$ vs the surgery group.

sustained neointimal hyperplasia. An increased extracellular matrix was the main histological change (Fig. 1E). Compared with surgery group, the VSMC proliferation and VSMC migration in valsartan-treated group were obviously attenuated on 14th day (Fig. 1C)

and 28th day (Fig. 1F) post-surgery. The image analysis results showed that valsartan significantly attenuated the intimal (Fig. 1G) and medial (Fig. 1H) thicknesses, compared to the untreated balloon-injured rats (all $p < 0.01$).

Effects of valsartan on aortic levels of angiotensin II, eNOS, and iNOS

Angiotensin II, eNOS, and iNOS expression levels in the aorta were shown in Fig. 2. On days 14 and days 28 post-surgery, the aortic angiotensin II (Fig. 2A) and iNOS (Fig. 2C) levels of the surgery rats were markedly increased, whereas, the aortic eNOS expression levels (Fig. 2B) in the surgery rats were significantly reduced, compared to those of the sham controls (all $p < 0.01$). In contrast, at both 14 and 28 days post-surgery, the administration of valsartan markedly reduced the aortic levels of angiotensin II and iNOS, and increased the aortic levels of eNOS, compared to the untreated balloon-injured rats (all $p < 0.05$). However, still increased angiotensin II and iNOS expression levels, and decreased eNOS expression levels were seen in rat aorta of valsartan group compared with controls (all $p < 0.05$).



Effects of valsartan on aortic TLR4, AT1 receptor, and AT2 receptor mRNA expression

RT-PCR analysis showed that, compared to the sham controls, the TLR4 (Fig. 3A) and AT1 receptor (Fig. 3B) mRNA expression levels were significantly increased in the surgery rats on days 14 and 28 post-surgery (all $p < 0.01$). In contrast, the mRNA expression of AT2 receptor (Fig. 3C) was markedly reduced in the surgery rats ($p < 0.01$). Importantly, treatment with valsartan for both 14 and 28 days markedly reduced the TLR4 and AT1 receptor mRNA expression, and increased the AT2 receptor mRNA expression, compared to the surgery rats (all $p < 0.05$). However, compared to the controls, TLR4 and AT1 receptor expression was still increased, and AT2 was decreased in valsartan group (all $p < 0.05$).

Fig. 3. Effects of valsartan on the aortic TLR4, AT1 receptor, and AT2 receptor mRNA expression. RT-PCR analyses of the aortic TLR4 (A), AT1 receptor (B), and AT2 receptor (C) mRNA expression following valsartan treatment in rats. GAPDH was used as an internal control. Data are shown as the mean \pm SD (n=6). * $p < 0.05$, ** $p < 0.01$ vs the control group, and $\Delta p < 0.05$ vs the surgery group.

Effects of valsartan on aortic TLR4, AT1 receptor, AT2 receptor, and p-ERK protein expression

Effect of valsartan on aortic TLR4, AT1 receptor, AT2 receptor, and p-ERK protein expression was evaluated at 14 and 28 days after surgery using Western blot assay (Fig. 4A). It was shown that aortic TLR4 (Fig. 4B), AT1 receptor (Fig. 4C), and p-ERK (Fig. 4E) protein expressions were markedly upregulated in the surgery rats, whereas, AT2 receptor (Fig. 4D) protein expression was markedly decreased, compared to the sham controls (all $p < 0.01$). Treatment with valsartan for both 14 and 28 days markedly reduced the protein

expression of TLR4, AT1 receptor, and p-ERK as well as increased the AT2 receptor protein expression, compared to the surgery group (all $p < 0.05$). In addition, compared to the controls, the expression of TLR4, p-ERK and AT1 receptor was still increased, and AT2 receptor was decreased in valsartan group (all $p < 0.05$).

Effects of valsartan on aortic SRSF1 protein expression

SRSF1 protein expression was measured by immunofluorescence assay in control, surgery and valsartan groups at 14 and 28 days after surgery. It was suggested that, aortic SRSF1 expression was increased

obviously in the surgery rats (Fig. 5B,E) than in the sham controls (Fig. 5A,D). When valsartan given for both 14 (Fig. 5C) and 28 (Fig. 5F) days, SRSF1 expression all

decreased significantly in comparison with the surgery group, but it was still higher than the controls.




Fig. 4. Effects of valsartan on aortic TLR4, AT1 receptor, AT2 receptor, and p-ERK protein expression. At 14 and 28 days after surgery, protein expression of TLR4, AT1 and AT2 receptors, and p-ERK was evaluated by Western blot assay (A). Quantifications of TLR4 (B), AT1 receptor (C), AT2 receptor (D), and p-ERK (E) protein expression relative to that of β -actin. Data are shown as the mean \pm SD (n=6). * p <0.05, ** p <0.01 vs the control group, and Δp <0.05 vs the surgery group.

Discussion

The results of the current study indicated that: 1) valsartan at a dose of 20 mg/kg/day treated balloon-injured rats for both 14 and 28 days significantly inhibited the neointimal hyperplasia and reduced the aortic SRSF1 expression, 2) valsartan decreased the aortic angiotensin II and iNOS levels while increased the aortic eNOS level, and 3) valsartan downregulated the TLR4 and AT1 receptor while upregulated the AT2 receptor mRNA and protein expression.

Valsartan also decreased the aortic p-ERK protein expression. These findings suggest that the therapeutic potential of valsartan in attenuating neointimal hyperplasia and inhibiting the TLR4-iNOS-ERK-AT1 receptor pathway and SRSF1 expression in balloon-injured rat aorta.

The proliferation of VSMCs is pivotal to intimal hyperplasia and finally leads to restenosis after angioplasty and atherogenesis (Yuan *et al.* 2017). SRSF1 is the prototypical member of the highly conserved SR protein family that functions in key aspects of mRNA




Fig. 5. Effects of valsartan on protein expression of SRSF1. Protein expression of SRSF1 was determined using immunofluorescence in 14 days (A, B, C) and 28 days (D, E, F).

metabolism. SRSF1 is highly expressed in VSMCs and actively involved in the alternative splicing events that shape the transcriptome of proliferative VSMCs (Llorian *et al.* 2016). We found that SRSF1 is upregulated in VSMCs during neointima formation, indicating that SRSF1 promotes VSMC proliferation and neointimal thickening. Furthermore, a previous study has manifested that SRSF1 promotes vascular smooth muscle cell proliferation through a D133p53/KLF5 pathway (Xie *et al.* 2017). Inflammation causes the initiation and development of restenosis. Increasing evidence indicates that inflammatory factor TLR4 activates the gene expression of proinflammatory cytokines (Goulopoulou *et al.* 2016). As an important transmembrane receptor in the human immune response, TLR4 is widely expressed in cardiomyocytes, endothelial cells, VSMCs, leukocytes, macrophages, etc. Importantly, a higher mRNA and protein expression of TLR4 and its downstream signaling proteins was found in restenosis patients (Liang *et al.* 2016). TLR4 recognizes and responds against lipopolysaccharides (LPS), and activation of TLR4 by LPS induces the release of inflammatory cytokines and the stimulation of the nuclear factor kappa B (NF- κ B) signaling pathway, ultimately initiating or promoting atherosclerotic lesions (Song *et al.* 2017). Everolimus-eluting stents reduce PCI induced increase in the TLR4 expression on the surface of monocytes (Shokri *et al.* 2015). Notably, TLR4 also plays an important role in nonbacterial inflammatory responses (Vallejo 2011), and

may serve as a link between inflammation and atherosclerotic lesions. TLR4 activates p38 mitogen-activated protein kinase (MAPK) and ERK1/2 signaling through myeloid differentiation factor 88 (MyD88) and TIR-domain-containing adapter-inducing interferon- β (TRIF) in VSMCs to regulate VSMC functions (Lee *et al.* 2016). Therefore, inhibition of TLR4 and its upstream signaling molecules provides therapeutic potential for treating restenosis. In the current study, on days 14 and 28 post-surgery, histological analysis demonstrated rat aortic neointimal hyperplasia in balloon-injured rats, which was associated with the increased mRNA and protein expression of TLR4. Treatment with valsartan markedly decreased the TLR4 mRNA and protein expression, concomitant with a reduction in neointimal hyperplasia. Our findings reveal that targeting TLR4 may have therapeutic potential for attenuating neointimal hyperplasia. Endothelial denudation is a prominent characteristic of vascular injury associated with angioplasty. Vascular injury leads to a decreased eNOS production (Hu *et al.* 2019). In an attempt to offset the absence of eNOS, there is a compensatory upregulation of iNOS within VSMCs (Kibbe, 1999). Inducible NOS contributes to the pathophysiology of inflammatory diseases. In addition, increased TLR4 expression can promote the production of iNOS by increasing the expression of proinflammatory cytokines (Heo *et al.* 2008). The current study showed the increased aortic levels of iNOS and decreased aortic levels of eNOS in the

untreated balloon-injured rats. Accordingly, abnormal aortic levels of iNOS and eNOS are reversed by the administration of valsartan. Angiotensin II promotes VSMC proliferation and migration, which contribute to the progression of neointimal hyperplasia. Angiotensin II acts via AT1 receptor and AT2 receptor. Apart from its vascular effects, angiotensin II also triggers an inflammatory response in human VSMCs (Granger *et al.* 2004, Ji *et al.* 2009). TLR4 upregulation by angiotensin II contributes to inflammation and endothelial dysfunction (de Batista *et al.* 2014, Hernanz *et al.* 2015). Angiotensin II also increased SRSF1 expression at the mRNA and protein levels in a time-dependent manner (Xie *et al.* 2017). ERK1/2 has been demonstrated to be involved in the pathological process of restenosis after coronary vascular injury (Sarav-Blat *et al.* 2010). Activation of ERK can promote VSMC proliferation or migration as well as accelerate neointimal hyperplasia. It is confirmed that Klotho inhibits proliferation and migration of angiotensin II-induced VSMCs by modulating NF- κ B p65, protein kinase B (Akt), and ERK signaling activities (Yu *et al.* 2018). Valsartan is a highly selective AT1 receptor blocker (Huang *et al.* 2014). In this study, we found that it can downregulate the expression of SRSF1 in balloon-injured

aorta, and this is not reported before. Consistent with our study, valsartan has been shown to inhibit high-glucose-induced TLR4 expression (Kintscher *et al.* 2010) and myocardial ischemia-reperfusion injury associated with TLR4 expression (Yang *et al.* 2009). Also, our study indicated that valsartan markedly reduces the aortic angiotensin II level, SRSF1 expression, AT1 receptor expression, and ERK protein phosphorylation as well as increases AT2 receptor expression.

In conclusions, this study indicated that the administration of valsartan for both 14 and 28 days after surgery reduced neointimal hyperplasia, and inhibited SRSF1 expression and the TLR4-iNOS-ERK-AT1 receptor pathway in the balloon-injured rat aorta.

Conflict of Interest

There is no conflict of interest.

Acknowledgements

This work was supported by the Key Project of Research and Development of Shandong Province (No.2018GSF118241), the National Nature Science Foundation of China (No.81800238) and the Natural Science Foundation of Shandong Province (No. ZR2016HP17).

References

- ALRAIES MC, DARMOCH F, TUMMALA R, WAKSMAN R: Diagnosis and management challenges of in-stent restenosis in coronary arteries. *World J Cardiol* 9: 640-651, 2017. <https://doi.org/10.4330/wjc.v9.i8.640>
- ARAÚJO PV, RIBEIRO MS, DALIO MB, ROCHA LA, VIARO F, DELLALIBERA JOVILIANO R, PICCINATO CE, ÉVORA PR, JOVILIANO EE: Interleukins and inflammatory markers in in-stent restenosis after femoral percutaneous transluminal angioplasty. *Ann Vasc Surg* 29: 731-737, 2015. <https://doi.org/10.1016/j.avsg.2014.12.006>
- BUCCHERI D, PIRAINO D, ANDOLINA G, CORTESE B: Understanding and managing in-stent restenosis: a review of clinical data, from pathogenesis to treatment. *J Thorac Dis* 8: E1150-E62, 2016. <https://doi.org/10.21037/jtd.2016.10.93>
- CHYU KY, DIMAYUGA P, ZHU J, NILSSON J, KAUL S, SHAH PK, CERCEK B: Decreased neointimal thickening after arterial wall injury in inducible nitric oxide synthase knockout mice. *Circ Res* 85: 1192-1198, 1999. <https://doi.org/10.1161/01.RES.85.12.1192>
- DE BATISTA PR, PALACIOS R, MARTIN A, HERNANZ R, MEDICI CT, SILVA MA, ROSSI EM, AGUADO A, VASSALLO DV, SALAICES M, ALONSO MJ: Toll-like receptor 4 upregulation by angiotensin II contributes to hypertension and vascular dysfunction through reactive oxygen species production. *PLoS One* 9: e104020, 2014. <https://doi.org/10.1371/journal.pone.0104020>
- DEN DEKKER WK, CHENG C, PASTERKAMP G, DUCKERS HJ: Toll like receptor 4 in atherosclerosis and plaque destabilization. *Atherosclerosis* 209: 314-320, 2010. <https://doi.org/10.1016/j.atherosclerosis.2009.09.075>
- FORSTERMANN U, SESSA WC: Nitric oxide synthases: regulation and function. *Eur Heart J* 33: 829-837, 37a-37d, 2012. <https://doi.org/10.1093/eurheartj/ehr304>
- GRANGER DN, VOWINKEL T, PETNEHAZY T: Modulation of the inflammatory response in cardiovascular disease. *Hypertension* 43: 924-931, 2004. <https://doi.org/10.1161/01.HYP.0000123070.31763.55>

- GOULOPOULOU S, MCCARTHY CG, WEBB RC: Toll-like Receptors in the Vascular System: Sensing the Dangers Within. *Pharmacol Rev* 68: 142-167, 2016. <https://doi.org/10.1124/pr.114.010090>
- GUIHUA L, WANG L, SANQING J, REN W, LIN Z, DAOKUO Y, RONGJING D: Influence of valsartan-eluting stent on neointima formation. *J Cardiovasc Dis Res* 1: 19-22, 2010. <https://doi.org/10.4103/0975-3583.59980>
- HADI NR, AL-AMRAN FG, HUSSIEN YA, AL-YASIRI IK, AL-TURFY M: The cardioprotective potential of valsartan in myocardial ischaemia reperfusion injury. *Cent Eur J Immunol* 40: 159-166, 2015. <https://doi.org/10.5114/ceji.2015.52829>
- HUANG QF, LI Y, WANG JG: Overview of clinical use and side effect profile of valsartan in Chinese hypertensive patients. *Drug Des Devel Ther* 8: 79-86, 2014. <https://doi.org/10.2147/DDDT.S38617>
- IWASHITA M, SAKODA H, KUSHIYAMA A, FUJISHIRO M, OHNO H, NAKATSU Y, FUKUSHIMA T, KUMAMOTO S, TSUCHIYA Y, KIKUCHI T, KURIHARA H, AKAZAWA H, KOMURO I, KAMATA H, NISHIMURA F, ASANO T: Valsartan, independently of AT1 receptor or PPARgamma, suppresses LPS-induced macrophage activation and improves insulin resistance in cocultured adipocytes. *Am J Physiol Endocrinol Metab* 302: E286-296, 2012. <https://doi.org/10.1152/ajpendo.00324.2011>
- HEO SK, YUN HJ, NOH EK, PARK WH, PARK SD: LPS induces inflammatory responses in human aortic vascular smooth muscle cells via Toll-like receptor 4 expression and nitric oxide production. *Immunol Lett* 120: 57-64, 2008. <https://doi.org/10.1016/j.imlet.2008.07.002>
- HERNANZ R, MARTINEZ-REVELLES S, PALACIOS R, MARTIN A, CACHOFEIRO V, AGUADO A, GARCÍA-REDONDO L, BARRÚS MT, DE BATISTA PR, BRIONES AM, SALAICES M, ALONSO MJ: Toll-like receptor 4 contributes to vascular remodelling and endothelial dysfunction in angiotensin II-induced hypertension. *Br J Pharmacol* 172: 3159-3176, 2015. <https://doi.org/10.1111/bph.13117>
- HU Z, WANG H, FAN G, ZHANG H, WANG X, MAO J, ZHAO Y, AN Y, HUANG Y, LI C, CHANG L, CHU X, LILI, LI Y, ZHANG Y, QIN G, GAO X, ZHANG B: Danhong injection mobilizes endothelial progenitor cells to repair vascular endothelium injury via upregulating the expression of Akt, eNOS and MMP-9. *Phytomedicine* 61: 152850, 2019. <https://doi.org/10.1016/j.phymed.2019.152850>
- JANSSENS S, FLAHERTY D, NONG Z, VARENNE O, VAN PELT N, HAUSERMANS C, ZOLDHELYI P, GERARD R, COLLEN D: Human endothelial nitric oxide synthase gene transfer inhibits vascular smooth muscle cell proliferation and neointima formation after balloon injury in rats. *Circulation* 97: 1274-1281, 1998. <https://doi.org/10.1161/01.CIR.97.13.1274>
- JI Y, LIU J, WANG Z, LIU N: Angiotensin II induces inflammatory response partly via toll-like receptor 4-dependent signaling pathway in vascular smooth muscle cells. *Cell Physiol Biochem* 23: 265-276, 2009. <https://doi.org/10.1159/000218173>
- JOVILIANO EE, PICCINATO CE, DELLALIBERA-JOVILIANO R, MORIYA T, EVORA PR: Inflammatory markers and restenosis in peripheral percutaneous angioplasty with intravascular stenting: current concepts. *Ann Vasc Surg* 25: 846-855, 2011. <https://doi.org/10.1016/j.avsg.2011.02.026>
- KIBBE M, BILLIAR T, TZENG E: Inducible nitric oxide synthase and vascular injury. *Cardiovasc Res* 43: 650-657, 1999. [https://doi.org/10.1016/S0008-6363\(99\)00130-3](https://doi.org/10.1016/S0008-6363(99)00130-3)
- KINTSCHER U, MARX N, MARTUS P, STOPPELHAAR M, SCHIMKUS J, SCHNEIDER A, WALCHER D, KÜMMEL A, WINKLER R, KAPPERT K, DÖRFFEL Y, SCHOLZE J, UNGER T: Effect of high-dose valsartan on inflammatory and lipid parameters in patients with Type 2 diabetes and hypertension. *Diabetes Res Clin Pract* 89: 209-215, 2010. <https://doi.org/10.1016/j.diabres.2010.04.018>
- LEE GL, WU JY, TSAI CS, LIN CY, TSAI YT, LIN CS, WANG YF, YET SF, HSU YJ, KUO CC: TLR4-Activated MAPK-IL-6 Axis Regulates Vascular Smooth Muscle Cell Function. *Int J Mol Sci* 17: E1394, 2016. <https://doi.org/10.3390/ijms17091394>
- LIANG S, AIQUN M, JIWU L, PING Z: TLR3 and TLR4 as potential clinical biomarkers for in-stent restenosis in drug-eluting stents patients. *Immunol Res* 64: 424-430, 2016. <https://doi.org/10.1007/s12026-015-8685-6>
- LI K, DING WH, SHI LB, ZHANG LF, HAN XN, TANG CS: Role of vascular remodeling for urotensin II in rat thoracic aorta after balloon injury. *Chin J Pathophys* 4: 674-679, 2008.
- LI Y, CAI S, WANG Q, ZHOU J, HOU B, YU H, GE Z, GUAN R, LIU X: Valsartan attenuates intimal hyperplasia in balloon-injured rat aortic arteries through modulating the angiotensin-converting enzyme 2-angiotensin-(1-7)-Mas receptor axis. *Arch Biochem Biophys* 598: 11-17, 2016. <https://doi.org/10.1016/j.abb.2016.03.028>

- LI YH, AN Y, WANG QX, MAN YL, LIU P, REN BB: Effects of valsartan on aortic angiotensin converting enzyme 2 expression after aortic balloon injury in rats. *Zhonghua Xin Xue Guan Bing Za Zhi* 40: 697-701, 2012.
- LI Y, WANG Q, XU Q, CAI S, ZHOU J, REN B, SUN T, LIU X, YU H: Valsartan decreases neointimal hyperplasia in balloon-injured rat aortic arteries by upregulating HO-1 and inhibiting angiotensin II type 1 receptor. *Life Sci* 110: 70-76, 2014. <https://doi.org/10.1016/j.lfs.2014.06.021>
- LLORIAN, M. GOODING C1, BELLORA N, HALLEGGER M, BUCKROYD A, WANG X, RAJGOR D, KAYIKCI M, FELTHAM J, ULE J, EYRAS E, SMITH CWJ: The alternative splicing program of differentiated smooth muscle cells involves concerted non-productive splicing of post-transcriptional regulators. *Nucleic Acids Res* 44: 8933-8950, 2016. <https://doi.org/10.1093/nar/gkw560>
- SAROV-BLAT L, MORGAN JM, FERNANDEZ P, JAMES R, FANG Z, HURLE MR, BAIDOO C, WILLETTE RN, LEPORE JJ, JENSEN SE, SPRECHER DL: Inhibition of p38 mitogen-activated protein kinase reduces inflammation after coronary vascular injury in humans. *Arterioscler Thromb Vasc Biol* 30: 2256-2263, 2010. <https://doi.org/10.1161/ATVBAHA.110.209205>
- SHOKRI M, BAGHERI B, GARJANI A, SOHRABI B, HABIBZADEH A, KAZEMI B, MOVASSAGHPUR AA: Everolimus-eluting stents reduce monocyte expression of toll-like receptor 4. *Adv Pharm Bull* 5 (Suppl 1): 643-647, 2015. <https://doi.org/10.15171/apb.2015.087>
- SONG Y, HOU M, LI Z, LUO C, OU JS, YU H, YAN J, LU L: TLR4/NF-kappaB/Ceramide signaling contributes to Ox-LDL-induced calcification of human vascular smooth muscle cells. *Eur J Pharmacol* 794: 45-51, 2017. <https://doi.org/10.1016/j.ejphar.2016.11.029>
- PARAMASIVAM G, DEVASIA T, JAYARAM A, U K AR, RAO MS, VIJAYVERGIYA R, NAYAK K: In-stent restenosis of drug-eluting stents in patients with diabetes mellitus: Clinical presentation, angiographic features, and outcomes. *Anatol J Cardiol* 23: 28-34, 2020. <https://doi.org/10.14744/AnatolJCardiol.2019.72916>
- PETERS S: Comparison of efficacy of low- (80 mg/day) and high- (160-320 mg/day) dose valsartan in the prevention of in-stent restenosis after implantation of bare-metal stents in type B2/C coronary artery lesions. *Am J Cardiovasc Drugs* 8(2): 83-87, 2008. <https://doi.org/10.1007/BF03256585>
- VALLEJO JG: Role of toll-like receptors in cardiovascular diseases. *Clin Sci (Lond)* 121: 1-10, 2011. <https://doi.org/10.1042/CS20100539>
- XIE N, CHEN M, DAI R, ZHANG Y, ZHAO H, SONG Z, ZHANG L, LI Z, FENG Y, GAO H, WANG L, ZHANG T, XIAO RP, WU J, CAO CM: SRSF1 promotes vascular smooth muscle cell proliferation through a $\Delta 133p53/EGR1/KLF5$ pathway. *Nat Commun* 8: 16016, 2017. <https://doi.org/10.1038/ncomms16016>
- YANG J, JIANG H, YANG J, DING JW, CHEN LH, LI S, ZHANG XD: Valsartan preconditioning protects against myocardial ischemia-reperfusion injury through TLR4/NF-kappaB signaling pathway. *Mol Cell Biochem* 330: 39-46, 2009. <https://doi.org/10.1007/s11010-009-0098-1>
- YONEDA S, ABE S, KANAYA T, ODA K, NISHINO S, KAGEYAMA M, TAGUCHI I, MASAWA N, INOUE T: Late-phase inflammatory response as a feature of in-stent restenosis after drug-eluting stent implantation. *Coron Artery Dis* 24: 368-373, 2013. <https://doi.org/10.1097/MCA.0b013e32836222ec>
- YUAN L, DUAN X, DONG J, LU Q, ZHOU J, ZHAO Z, BAO J, JING Z: p21-Activated kinase 4 promotes intimal hyperplasia and vascular smooth muscle cells proliferation during superficial femoral artery restenosis after angioplasty. *Biomed Res Int* 2017: 5296516, 2017. <https://doi.org/10.1155/2017/5296516>
- YU S, CHEN Y, CHEN S, YE N, LI Y, SUN Y: klotho inhibits proliferation and migration of angiotensin ii-induced vascular smooth muscle cells (VSMCs) by modulating NF-kappaB p65, akt, and extracellular signal regulated kinase (ERK) signaling activities. *Med Sci Monit* 24: 4851-4860, 2018. <https://doi.org/10.12659/MSM.908038>
- ZAQOUT S, BECKER LL, KAINDL AM: Immunofluorescence staining of paraffin sections step by step. *Front Neuroanat* 14: 582218, 2020. <https://doi.org/10.3389/fnana.2020.582218>
- ZOU G, ZHU J, LIU Z, WU L, XU R, CHEN H, DENG P, DENG C: Detoxification and activating blood circulation decoction reduces restenosis involving the TLR4/NF- κ B pathway after balloon injury. *Prostaglandins Other Lipid Mediat* 140: 1-8, 2019. <https://doi.org/10.1016/j.prostaglandins.2018.11.002>